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1 Abstract 
A procedure for protein and peptide loading using beta glucan particles (GPs) had been 
developed been developed that required repetitive mixing in small volumes in tubes (Huang et. al, 
2010). The goal of this project was to increase the efficiency of this protein encapsulation process 
by developing high throughput loading conditions in 96-well plates. Once ideal conditions for 
high-throughput loading methods were established, we evaluated methods to load cysteine-
containing peptide binding using GPs derivatized with the heterobifunctional cross linker N-
succinimidyl S-acetylthioacetate (SATA, 231.23 g.mol) and a new activated thiol crosslinking 
method with 2,2'-dithiolethyl bis(4-azido-2,3,5,6-tetrafluorobenzoate) (DAT, 224.25 g/mol). 
Further analysis of peptide loading was done using fluorescent and N-Pyr(Cys) peptide binding, 
and in vitro immunological experiments. The results of the 96-well plate loading method 
demonstrated that the best method for high-throughput loading was, in fact an adaptation of the 
original procedure for loading beta glucan particles in particles in 96-well plates.   This method 
loaded proteins in fifty percent of the hydrodynamic volume of the particles followed by a water 
push of twenty-five percent of the hydrodynamic volume and trapping inside GPs as an albumin-
yeast RNA nanocomplex. Analysis of both the SATA cross linker method and the new approach 
using DAT revealed that the SATA-derivatized particles had a higher degree of functionalization 
in comparison to the DAT-derivatized particles. Ellman’s Assay used to measure incorporated 
thiol onto the branched polyethyleneimine-labeled SATA particles showed 7.10 x 104 molecules 
of thiol bound per GP, while DAT particles showed 7.00 x 103 molecules of thiol bound per GP. 
Immunological testing for GP mediated peptide delivery to dendtritic cell-OT-II T-cells is 
underway. Immunological testing to assess the functional activity of GP-peptide linked through 
linear PEI/SATA versus DAT revealed that DAT-derivatized GPs stimulated a stronger immune 
response in murine OT-II cells than linear PEI/SATA-derivatized GPs. In addition, immunological 
testing to assess the functional activity of Ova protein-loaded GPs versus IgG- and lysozyme-
loaded GPs showed that GPs loaded with Ova protein and with IgG, both in the 96-well plate and 
in tubes, stimulated a T-cell response. 
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6 Introduction 
6.1 Immune System 
The immune system of vertebrates is designed to respond to microbes that could pose a 
threat to the organism. There are two branches of the immune system, innate immunity and 
adaptive immunity, which make up this defense. The innate immune system is designed to respond 
immediately to infection and is mostly made up of phagocytic cells, such as neutrophils and 
macrophages, which are activated by pathogens via germ-line encoded receptors. These cells 
recognize structures found on most microorganisms, such as PAMPs (pathogen associated 
molecular patterns), and are responsible for destroying infected cells and pathogens (Akira & 
Hemmi, 2003). The innate immune system can also produce cytokines and chemokines, which 
activate adaptive immunity (Clark, Kerrigan & Brown, 2011).  
The adaptive immune system is largely made up of B- and T-cells. B-cells play a large role 
in host defense by either serving as an antigen presenting cell to activate T-cells or by producing 
antibodies which will neutralize foreign antigens. After antigen clearance, a small number of 
effector B-cells develop into memory B-cells, which allow for quick recall responses to the initially 
encountered antigen (LaRosa & Orange, 2008). This feature is known as immunological memory 
and is the hallmark of the adaptive immune system.  
There are several subsets of T-cells, including helper T-cells and cytotoxic T-cells. Helper 
T-cells serve several roles, including the maturation of B-cells or the activation of cytotoxic T-
cells. Helper T-cells are activated to produce cytokines upon recognition of foreign antigens 
presented by MHC class II molecules on the surface of antigen presenting cells. In contrast to 
helper T-cells, the main role of cytotoxic T-cells is to kill virally-infected cells or cancer cells. 
Cytotoxic T-cells recognize MHC class I molecules presenting foreign and self-antigens. Like B-
cells, a subset of helper and cytotoxic T-cells develop into long lasting memory T-cells that can be 
rapidly reactivated when challenged with the original antigen.  
 
6.2 Vaccines 
The major goal of vaccination is to help prevent subsequent infections. Vaccines were first 
developed by Edward Jenner who realized that milkmaids who were previously exposed to cowpox 
were protected against smallpox. The common practice for protecting against smallpox at the time 
was variolation, a practice where smallpox matter was introduced to a patient in order to prevent 
them from getting the disease. Unfortunately, this practice caused some patients to get the disease, 
which occasionally began a small epidemic. When Jenner realized cowpox made a person immune 
to smallpox, he introduced matter from a fresh cowpox lesion to a boy and then later introduced 
matter from a smallpox lesion. The boy did not get smallpox, so Jenner concluded that the 
protection was complete (Riedel, 2005). Vaccines are designed to generate immunological 
memory, so that memory B and T cells can quickly be activated when the body becomes re-infected 
with a pathogen containing the previously exposed to antigen. Vaccines can be developed using 
components from a given pathogen such as crude extracts, proteins, MAPs, and peptides (Huang 
et. al, 2010).  
 
6.3 Beta-Glucan Particles 
Beta-glucan particles (GPs) are 3-4μm hollow particles extracted from Saccharomyces 
cerevisiae (baker’s yeast). Beta-glucan particles are prepared by treating the walls of the yeast cells 
so that the cell wall components and soluble proteins are removed. GPs are composed of β-1-3-D-
glucan and residual chitin (Yan et al., 2005). These GPs can be loaded with payload molecules and 
used to deliver these molecules into a cell (Brown and Gordon, 2001). Receptors on the surface of 
phagocytic cells, dectin-1 and Complement Receptor-3 (or CR3), recognize beta-glucans, allowing 
targeted delivery of the drug into macrophages and dendritic cells (Sanders and Hendrin, 1997). 
The use of GPs for the delivery of macromolecules, such as DNA, siRNAs, and protein antigens, 
has been successfully demonstrated both in vitro and in vivo (Soto and Ostroff, 2008; Aouadi et 
al., 2009).    
 
6.4 Protein Loading Method 
The standard method for loading and trapping macromolecules inside the porous β -glucan 
particles involves hand mixing the macromolecule in a volume of liquid completely absorbed by 
the hollow sponge-like glucan particles inside a microcentrifuge tube. This initial step is followed 
by several “water-push” steps where water is mixed with the lyophilized GP protein powder in the 
tube in order to push by capillary action a greater percentage of the macromolecules inside the GP, 
altering the concentration gradient across the porous surface. The molecules are then trapped inside 
the GP by an albumin-yeast RNA nanocomplex, allowing the molecules to remain inside the 
particle until the substance is released by proteolysis in the phagolysosome after having been taken 
up by a phagocytic cell (Huang et. all, 2010). A visual representation of this can be seen in Figure 
1. The use of yeast RNA as a trapping polymer for macromolecules in β-glucan particles was 
demonstrated by Ostroff and typical encapsulation efficiencies of 95+% are attainable. This 
laborious hands-on tube method of GP loading, however, is not well suited for high-throughput 
loading to build GP peptide or protein antigen libraries (Negmetzhanov, 2012). 
 
 Figure 1: Standard loading of proteins into GPs 
 
6.5 Peptide Binding Method 
In addition to loading molecules inside the GPs, chemically active residues can be bound 
to the GP shells. This option provides an alternative method for GP payload delivery and was 
investigated as a way to better load peptides because the peptides do not bind well in the albumin 
tRNA matrix used for trapping molecules inside the GPs. To study this idea, different techniques 
of binding peptides to the surface were examined (Negmetzhanov, 2012).  
 
6.6 SATA Modified GP Binding Method  
β-glucan particles can be derivatized with various molecules to allow peptides and other 
such molecules to be bound to the surface for delivery to macrophage cells. To activate the neutral 
glucan polysaccaride particles, different cationic polymers, such as chitosan or PEI, can be added 
to the surface of GPs to establish an electrostatic or covalent payload binding mechanism. These 
cationic Polyethyleneimine-GPs and Chitosan-GPs can then have their surface further derivatized 
with N-Sucinimidyl S-Acetylthioacetate (SATA), a sulfhydryl-containing modification reagent 
that reacts with primary amines (-NH2). Such amines are found on the side chain of antibodies and 
proteins. Treating protected sulfhydryl groups created by SATA with hydroxylamine yields free 
sulfhydryl groups. These sulfhydryl groups are then used for disulfide bond conjugation reactions 
to bind thiol-containing Cysteine-peptides. Binding peptides to the surface of the GPs is a way to 
deliver the peptides to macrophages, which can be used for practical applications, such as vaccines. 
Unfortunately, this covalent linking method also produces ionic interaction side products that must 
be removed by performing a salt wash. This step could potentially be eliminated by developing a 
method that does not form these undesirable ionic interactions (Negmetzhanov, 2012). 
 
6.7 DAT 
One possible alternative to surface derivitization with SATA was to use a diazido 
compound. To attempt this process, the compound 2,2'-dithiolethyl bis(4-azido-2,3,5,6-
tetrafluorobenzoate) (DAT) was made. When exposed to UV radiation, the azide group of this 
compound breaks down, forming a nitrene that can directly attach to hydroxyls on the GP surface 
(Ohana et. al., 1995). However, DAT is not water soluble, so other solvents must be used. 
Additionally, the UV radiation necessary for breaking down this compound can be harmful for the 
GPs and prolonged exposure could cause them to break apart. Therefore, minimization of this 
exposure is essential. If these obstacles can be surmounted, then this method could be cheaper, 
faster, and more efficient then SATA modified GP coupling. 
 
6.8 OT-II T-cell Proliferation 
The unique structure of GPs allows recognition and uptake by phagocytic dendritic cells 
or macrophages (APCs; antigen presenting cells). We took advantage of transgenic T-cell mice 
containing CD4+ OT-II T-cells, which specifically recognize Ova protein or peptide as an MHC-
II antigen.  CD4+ OT-II T cells can be used for quantifying the functional response towards Ova 
core-loaded and Ova surface-bound GPs when used processed and presented by phagocytic APCs. 
The APCs recognize, uptake, and digest GPs along with the Ova payload for presentation to CD4+ 
OT-II T-cells. Once introduced to the Ova antigen, the T-cells mount an immune response and 
proliferate, which can be measured using a [3H]-thymidine T-cell proliferation assay (Huang et al., 
2010). Using this assay, we tested different N-Pyr(Cys) peptide Ova-surface linked GP samples 
utilizing the GP core loaded Ova sample as a control.  
 
 
  
7 Project Goals 
Vaccines are some of the most important methods for preventing infectious disease. β-
glucan particles (GPs) have been shown to be an effective method for delivery macromolecules. 
The first goal of this project was to develop a high-throughput method to load GPs with proteins 
in 96-well plates and to examine loading efficiency and biological activity of these particles. The 
second goal of this experiment was to bind peptides to the surface of GPs as an alternative to GP-
core loading. One such method is a GP-(NH2)n + SATA reaction, which, unfortunately, results in 
ionic interactions between N-Pyr(Cys) peptides and charged amine residues, preventing desired 
covalent linkages between SATA and the peptides. Optimization of the GP-(NH2)n + SATA 
reaction to saturate all primary amines and greatly increase overall peptide binding efficiency 
would be the desired outcome. In coordination with the second goal, a third objective was to 
examine an alternative conjugation approach using a newly synthesized compound 2,2'-
dithiolethyl bis(4-azido-2,3,5,6-tetrafluorobenzoate) for direct peptide linkage onto the surface of 
GPs. GP-core loaded Ova protein and GP-surface linked Ova peptide were tested using an OT-II 
T-cell assay for biological activity. This assessment allows comparison of these different 
protein/peptide vaccine delivery strategies, culminating all experiments. 
8 Materials 
8.1 Equipment 
A list of essential laboratory equipment used for the methods of this project includes: the 
Tecan Safire microplate reader from Tecan Austria GmbH (Austria), The Virtis lyophilizer from 
Virtis Company (Gardiner, NY), the 96-well Costar plates with UV transparent flat-bottom from 
Corning, Inc (Corning, NY), the 96-well Costar plates with 2 mL assay block from Corning, Inc 
(Corning, NY), the Eppendorf Centrifuge 5415 D (Hamburg, Germany), the Harvester96 cell 
harvester from Tomtec (Hamden, CT),  the Jouan C312 Centrifuge (Winchester, VA). Sonifier® 
Cell disrupter W185 from Heat Systems-Ultrasonics, Inc. (Plainview, LI, NY), the Sonifier® Cell 
disrupter W350 from Heat Systems-Ultrasonics, Inc. (Plainview, LI, NY), the Wallac 1450 
Microbeta® beta counter from PerkinElmer (Waltham, MA), the Axiovert 200M fluorescent 
microscope from Zeiss (Germany), and the a 460 Watt UV lamp from the University of 
Massachusetts at Lowell (Lowell, MA). 
 
8.2 Reagents 
A list of essential reagents used for the methods of this project includes: beta-glucan 
particles prepared from Fleishmans Baker’s yeast (AB Mauri Food Inc, Chesterfield, MO) 
according to previously published procedures (Soto and Ostroff, 2008); IgG from sheep IgG 
purchased from ImmunoReagents, Inc. (Raleigh, NC); Ovalbumin (Ova) from chicken egg white, 
Ribonucleic acid from torula yeast Type VI (tRNA), chitosan from crab shells, 1,3-
diaminopropane (DAP), 25 kDa branched polyethylenimine (PEI), 800 Da linear PEI, 
hydroxylamine hydroclochloride, ethylenediamine-tetraacetic acid (EDTA), acetic acid, and 
glycine purchased from Sigma-Aldrich (Allenstown, PA); cell tissue culture materials purchased 
from Gibco Scientific (Grand Island, NY); SATA (N-Succinimidyl S-Acetylthioacetate) 
purchased from Pierce Chemicals (Rockford, IL); thymidine, 1 µCi/well, from PerkinElmer 
(Boston, MA);  2,2'-dithiolethyl bis(4-azido-2,3,5,6-tetrafluorobenzoate) (DAT) synthesized in the 
lab of Yan MingDi at UMass Lowell (Lowell, MA); and N-Pyr(Cys) Ova-323-339-amide peptide 
(ISQAVHAAHAEINEAGR-amide, 90.12% purity) purchased from 21 Century Biochemicals 
(Marlborough, MA). 
  
9 Methods 
All methods represent the final procedures used in completing this project and generating 
results. 
 
9.1 High-throughput GP protein loading in 96-well plates 
9.1.1 Qualitative analysis of 96-well plate loading conditions 
Dry empty GP blanks of 5 mg (2.5x109 particles) were made in a 96-well plate properly 
sized for a 1 L lyophilization flask. To visualize loading uniformity, varying volumes (10 µL, 20 
µL, and 40 µL) of 1 mg/mL Trypan Blue dye in water as were used as a model payload for the 
primary load. The particles were centrifuged at 1000 rpm for 30 min, frozen to -80ºC, and 
lyophilized. A water push of varying volumes (5 µL, 10 µL, and 20 µL) was then done to complete 
the particle loading process. Particles were centrifuged at 1000 rpm for 30 min, frozen to -80ºC, 
and lyophilized. The effects of primary load volume and water push volume were evaluated by 
evenness of color in order to determine an ideal high-throughput sequence for loading GPs without 
hand mixing. 
 
9.1.2 Quantitative analysis of 96-well plate loading conditions 
Once ideal volume conditions for dye loading were found, loading of Fluorescein 
isothiocyanate-labeled Ovalbumin (FL-Ova) through yeast tRNA (yRNA) trapping was examined. 
Dry GP blanks of 5 mg were made in a 96-well plate properly sized for a 1 L lyophilization tube.  
Three sets of paired volumes and concentrations (20 µL at 25 mg/mL, 30 µL at 16.7 mg/mL, and 
40 µL at 12.5 mg/mL) of FL-Ova were added to individual unloaded GPs to keep the total moles 
of FL-BSA constant (11.1 nmoles). The plate was centrifuged at 1000 rpm for 30 min, frozen to -
80ºC, and lyophilized. A water push of 20 µL was done and the plate was centrifuged at 1000 rpm 
for 30 min, frozen to -80ºC, and lyophilized again. The process was repeated using a 10 µL water 
push. Yeast RNA trapping polymer (2x15 µL at 25 mg/mL) was added to the first set of particles, 
while saline (2x15 µL) was added to the second set to serve as controls. The plate was centrifuged 
for 5 min and incubated for 10 min at 50ºC. Yeast RNA (500 µL at 10 mg/mL) was added to the 
first set, while saline (500 µL) was added to the second control set. All wells were mixed by 
pipetting and the plate was incubated for 30 min at 50ºC. The plate was then centrifuged at 1000 
rpm for 30 min, and the supernatant of each well was transferred to a transparent, 96-well UV 
plate. MOPS buffer (100 uL, 0.1 M, pH = 7.5) was added to each well of the 96-well UV plate. 
Fluorescence was read with an excitation wavelength of 494 nm and an emission wavelength of 
518 nm. The results of primary load volume versus FL-OVA concentration were evaluated by 
calculating the average percent loading of each sample (N=3). An identical experiment was done 
inside tubes for comparison. All loaded GP samples were diluted to 1 mg/mL and imaged under 
the fluorescent microscope at 100x to assess loading of fluorescent payload. 
 
9.1.3 Macrophage Uptake Microscopy 
In order to determine if the particles made in the plate were biologically active, samples 
loaded with each of three fluorescently labeled proteins (IgG, Lysozyme, and Ovalbumin) inside 
the 96-well plate were added to a plate of macrophages in media (with a cover slip). Each sample 
was added to three wells in the macrophage plate. Blank GPs were used as a negative control and 
GFPs were used as a positive control.  After two hours of incubation, the first well of each sample 
was stopped by removing the cover slip and placing it into a well of a separate plate containing the 
next well for each sample was stopped at 8 hours and the last at 24 hours. The macrophages were 
then observed and imaged under the fluorescent microscope at 20x magnification. 
 9.2 Optimization of GP-NH2 + SATA reaction 
9.2.1 Polyamine coupling to GPs through periodate oxidation and 
borohydride reduction 
Dry, empty GPs (10 mg) were suspended in 750 µL water in 15 mL conical tubes. 
Potassium periodate (0.0043 M) was added to each tube. The mixture was stirred in the dark 
overnight. The resulting oxidized suspension was centrifuged and the supernatant was discarded. 
The GPs were washed 3 times with water and suspended in 800 µL water. Borate buffer (200 µL, 
0.1 M, pH = 9) was added to each tube and 500 µL of each 5 mg/mL polymer solution (Low MW 
Chitosan, Linear PEI, and Branched PEI) dissolved in water were added to individual tubes. Low 
MW Chitosan was dissolved in 0.1 M acetic acid and 500 µL water was added to the control. The 
particles were suspended and incubated in the dark at room temperature (RT) for 24 hrs. Borate 
buffer (1 mL, 0.1 M, pH = 9) and 2 mg sodium borohydride (powder) were added to each tube. 
The samples stirred at RT for 24 hrs and another 2 mg of sodium borohydride (powder) was added 
to each tube. After all the bubbles had dissipated (over 24 hrs), the samples were washed 8 times 
with water and suspended in 1 mL saline. The samples were then washed 3 times in water and 
suspended in 1 mL water at a 10 mg/mL or 5E09 GP/mL particle concentration and stored at -
20ºC. 
 
9.2.2 Heparin Assay 
Amine-coupled and control GP samples (0.2 mg) were suspended in 100 µL of PBS. 
Varying amounts of fluorescent rhodamine-heparin in 100 µL of 1X PBS were added to each tube. 
The samples were incubated for 1 hr at RT. The samples were centrifuged and 100 µL of the 
supernatants were transferred to a transparent 96-well UV plate. Fluorescence was measured at an 
excitation of 540 nm and emission of 577 nm. An EC50 value of the amount of heparin bound to 
the particles was calculated based on a fluorescent rhodamine-heparin titration curve. The 
remaining supernatant was discarded, and the samples were washed three times in 1X PBS. The 
particles were suspended in 1X PBS and imaged using a fluorescent microscope. 
 
9.2.3 SATA binding assay 
Amine-coupled GP samples (0.2 mg: Low MW Chitosan, Linear PEI, and Branched PEI) 
were suspended in 1X PBS. SATA (500 mM) was dissolved in DMSO. Varying amounts of SATA 
(5 µL, 37µL, and 29 µL) at a 1:1 molar ratio of SATA:amine based on the calculated heparin EC50 
binding values were added to each tube, respectively. The samples were incubated for 2 hr at RT 
in the dark. The samples were then washed three times with water. The supernatants were 
discarded and the samples were frozen and lyophilized for an Ellman’s Assay to measure 
conjugated thiols. 
 
9.2.4 Ellmans Assay – thiol standard curve 
A standard curve of cysteine (100 µL) (0, 0.01875, 0.0375, 0.075, 0.1875, 0.375, and 0.75 
µM) in sodium phosphate buffer (0.1 M, pH=8, 1mM EDTA) were made.  Sample dilutions (100 
µL) in sodium phosphate buffer (0.1 M, pH=8, 1mM EDTA) were made. A solution of Ellman’s 
Reagent (0.01M) in sodium phosphate buffer (0.1 M, pH=8, 1mM EDTA) was made, and 5 µL 
was added to each sample, excluding the control. The volume of each sample was increased to 200 
µL by adding sodium phosphate buffer. After 15 min of incubation in the dark, 100 µL of each 
sample was placed in a transparent 96-well plate and absorbance was measured at 412 nm. A graph 
of absorbance versus moles of cysteine was plotted and an equation was generated for quantifying 
sulfhydryl groups bound to GPs. 
 
9.2.5 Ellman’s Assay of SATA-conjugated samples 
A solution of hydroxylamine hydrochloride (HA-HCl) (0.50 M, pH = 7.4, 10 mM EDTA) 
was prepared in 1X PBS. HA-HCl (5 L) was added to each 0.2 mg SATA-conjugated GP sample 
to deprotect the thiol. The samples were sonicated and incubated for 2 hrs in the dark at RT. The 
samples were then washed three times with 1X PBS. A solution of sodium phosphate buffer (0.1 
M, pH = 8, 1 mM EDTA) was prepared. A solution of Ellman’s Reagent (0.01 M) in sodium 
phosphate buffer was made. Ellman’s Reagent (5 L) was added to each deprotected sample. After 
15 min of incubation, 195 L of sodium phosphate buffer was added to each sample. The samples 
were centrifuged, and 100 L of supernatant from each tube transferred to a transparent 96-well 
UV plate. Absorbance was measured at 412 nm, with a reference of 750 nm, and converted into 
moles of sulfhydryl bound per GP by using the equation of absorbance versus M cysteine 
generated from a cysteine standard curve. 
 
9.3 Alternative conjugation approach using DAT 
9.3.1 Coupling of DAT to GPs through photoactivation of an aryl azide 
Empty, dry GPs (10 mg) were suspended in 2 mL 75% acetone by volume and transferred 
to dram vials wrapped in aluminum foil. DAT (8 mL, 5.57 mM) in 75% acetone was added to each 
dram vial. The samples were incubated for 30 min on ice immediately under 450 Watt 280+ nm 
UV light to avoid light dissipation over distance. The suspensions were collected in 
microcentrifuge tubes, spun down and the supernatants discarded. Each sample was washed once 
in 100% acetone, twice in 75% acetone, and twice in water. The samples were suspended in 1.0 
mL saline and 200 L aliquots were made. The aliquots were centrifuged, the supernatant was 
discarded, and the tubes were frozen and lyophilized for an Ellman’s Assay to measure conjugated 
thiols. 
 
9.3.2 Ellman’s Assay of DAT-conjugated GP samples 
A solution of Tris(2-carboxyethyl)phosphine (TCEP) (0.125 M, pH = 7.4, 5 mM EDTA) 
was prepared in 1X PBS.TCEP (10 L) was added to each 0.2 mg DAT-conjugated GP sample to 
reduce the thiol. The samples were sonicated and incubated for 2 hrs in the dark at RT. The samples 
were then washed three times with 1X PBS. A solution of sodium phosphate buffer (0.1 M, pH = 
8, 1 mM EDTA) was prepared. A solution of Ellman’s Reagent (0.01 M) in sodium phosphate 
buffer was made. Ellman’s Reagent (5 L) was added to each deprotected sample. After 15 min 
of incubation, 195 L of sodium phosphate buffer was added to each sample. The samples were 
centrifuged, and 100 L of supernatant from each tube transferred to a transparent 96-well UV 
plate. Absorbance was measured at 412 nm, with a reference of 750 nm, and converted into moles 
of sulfhydryl bound per GP by using the equation of absorbance versus M cysteine generated 
from a cysteine standard curve. 
 
9.4 Analysis of SATA-conjugated and DAT-conjugated GP samples 
through N-Pyr(Cys) Ova peptide binding 
9.4.1 N-Pyr(Cys) Assay - peptide standard curve 
A standard curve of cysteine (100 µL) (0, 0.781, 0.156, 0.3125, 0.625, and 1.25 mM) in 
water were made. Sample dilutions (100 µL) in were made. A solution of N-Pyr(Cys) Ova peptide 
(2.5 mM) in water was made, and 10 µL was added to each sample, excluding the control. The 
volume of each sample was increased to 200 µL by adding water. After 15 min of incubation in 
the dark, 200 µL of each sample was placed in a transparent 96-well UV plate and absorbance was 
measured at 405 nm. A graph of absorbance versus moles of pyridine was plotted and an equation 
was generated for quantifying Cys Ova peptide bound to GPs. 
 
9.4.2 N-Pyr(Cys) Ova peptide binding assay of SATA-conjugated and DAT-
conjugated GP samples 
HA-HCl (5 L) was added to each SATA-conjugated GP sample to deprotect the thiol. 
TCEP (10 L) was added to each DAT-conjugated GP sample to reduce the thiol. The GP samples 
were sonicated and incubated for 2 hrs in the dark at RT. The samples were washed three times 
with 1X PBS. All samples were suspended in 5 L of water. N-Pyr(Cys) Ova peptide (5 L, 2.5 
mM) dissolved in water was added to each sample. Duplicates of each sample without addition of 
N-Pyr(Cys) Ova peptide were included, along with a control of only N-Pyr(Cys) Ova peptide in 
solution. The samples were incubated for 2 hr in the dark at RT. Water was added to make the 
final solution volume 200 L. The samples were centrifuged and the 200 L of supernatant from 
each sample was transferred to a transparent 96-well UV plate. Absorbance was read at 405 nm, 
with a reference of 750 nm. Absorbance was converted into moles of pyridine in solution, which 
was converted into moles of Cys Ova peptide bound per GP by using the equation of absorbance 
versus mM pyridine generated from a pyridine standard curve. 
 
9.5 Demonstration of biological utility of GP peptide 
9.5.1 OT-II T-cell proliferation assay 
Purified T-cells (105 cells/well) were incubated with mitomycin C-treated (Bone Marrow 
Dendritic Cells) BMDCs (106 cells/well) and various GP samples for 4 days in round-bottom 96-
well plates in 200 µL R10 medium. [3H]-thymidine was added for the last 24 hr of incubation. 
Each condition of GPs added was studied in triplicate. Cells were collected on filter paper using a 
harvester, and [3H]-thymidine incorporation was measured with a beta counter (Huang et al., 
2010). 
 
10 Results 
10.1 High-throughput GP protein loading in 96-well plates 
The standard protein loading of GPs requires repetitive mixing steps that make it 
impractical to produce peptide and protein antigen libraries. Avoiding these mixing steps while 
maintaining loading efficiency would improve experimental output. Therefore, high throughput 
methods of loading were tested by loading dyes into GPs in 96-well plates. The distribution of the 
dyes were examined and evaluated based on evenness of diffusion and deepness of color. Initial 
experiments used a color change reaction for loading dyes into GPs, but using multiple dyes 
produced variable results that were difficult to read. The clearest qualitative results were best 
shown by using a single dye. 
Using dyes for loading into GPs allowed for easily visible results showing how well the 
material spread and diffused throughout the particles without mixing by hand. Plates were prepared 
with blank GPs and loaded with dye (Figure 2). The plate was then spun in a centrifuge to distribute 
the dye and allowed to incubate so that the dye diffused throughout the particles. Sets of several 
wells in the plate were given a different amount of particles and volume of dye in order to 
determine the ideal amounts. The standard method of loading uses ½ the hydrodynamic volume 
(20 μL for 5 mg of GPs) of loading material. This experiment was done using ½x hydrodynamic 
volume (columns 1-4), ¾x hydrodynamic volume (columns 5-8), and 1x hydrodynamic volume 
(columns 9-12). The plate also contained different amounts of GPs to see if less particles at a time 
would result in more uniform distribution. Though the ideal size was at least 5mg of particles (rows 
1 and 2), amounts of 4 mg (rows 3 and 4), 3 mg (rows 5 and 6), and 2 mg (rows 7 and 8) were also 
tested. Each well condition had both a hand mixing (odd rows) and non-hand mixing (even rows) 
counterpart in order to determine if hand mixing significantly affected results. 
 Figure 2: GP Loading with Trypan Blue dye in 96-well plate 
Even rows were done with no mixing, Odd rows were done with mixing; Rows 1 & 2 contained 
5mg of GPs; Rows 3 & 4 contained 4mg GPs; Rows 5 & 6 contained 3mg of GPs; Rows 7 & 8 
contained 2mg GPs; Columns 1-4 contain GPs loaded with 20μL (1/2 the hydrodynamic volume) 
of 1 mg/mL Trypan Blue dye; Columns 5-8 contain GPs loaded with 30μL (3/4 the hydrodynamic 
volume) of 1 mg/mL Trypan Blue dye; Columns 9-12 contain GPs loaded with 40μL (1X the 
hydrodynamic volume) of 1 mg/mL Trypan Blue dye. 
 
The rows in the plate shown in Figure 2 alternated between hand mixing and plate mixing 
by centrifugation. The mixing wells (rows 1, 3, 5, and 7) did not mix together well, as can be seen 
by their clumped appearance and by the way the clumps stuck to the sides. The non-mixing wells 
were much more manageable in the plate. Wells using 1x hydrodynamic volume (columns 9-12) 
had too much dye and were not practical for use either with or without hand mixing. The remaining 
wells distributed nicely without having too much remaining liquid. Wells containing 5 mg of 
particles (rows 1 and 2) showed good distribution of dye even without mixing. 
Once the volume of dye that was best for uniform particle loading in a high throughput 
format was established, this new loading method needed to be quantified in order to determine 
how effectiveness of GP protein loading in 96-well plates. In order to quantify the efficiency of 
high throughput GP protein loading without mixing, fluorescent proteins were used. Particles were 
loaded in 96-well plates using fluorescent lysozyme (14 KDa), Ovalbumin (FL-Ova; 45 kDa) and 
immunoglobulin (IgG; 150 kDa). The amount of loading in the plate was determined by adding 
0.1 M MOPS buffer and measuring unincorporated florescence. The percent loading of FL-Ova in 
the plate was determined to be 98.78%, the percent loading for Lysozyme was 67.99%, and the 
percent loading for IgG was 56.46%. The Ova result was compared to the fluorescent reading of 
particles prepared in tubes, which was 98.83%, by taking the percent difference using the following 
calculation: 
% 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =
𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒
𝑎𝑣𝑒𝑟𝑎𝑔𝑒
=
98.83 − 98.78
98.83 + 98.78
2
= 0.0506% 
Plates of particles were set up with 5 mg of GPs per well and loaded with varying volume 
or concentration of fluorescent proteins to help determine the most effective volume/concentration 
combination for loading particles in the plate. The loading volumes of fluorescent Ova used were 
½x the hydrodynamic volume, ¾x the hydrodynamic volume, and 1x the hydrodynamic volume. 
The standard method used when loading is done in tubes is ½x the hydrodynamic volume (20 μL 
for 5 mg of GPs). First wells of ¾x and 1x hydrodynamic volume were loaded using the same 
concentration of protein as in the ½x hydrodynamic volume but different volumes (30 μL for ¾x 
and 40 μL for 1x). Next, samples were again made using ¾x and 1x hydrodynamic volume but 
this time they were done using the same volume (20 μL) as the ½x hydrodynamic volume (this 
varied concentration). These samples were observed under a fluorescent microscope to look for 
even loading distribution (Figure 3). 
 Figure 3: Images of GPs under a fluorescent microscope after loading in a 96-well plate. 
A) GPs loaded with 20μL (1/2 the hydrodynamic volume) of 25mg/mL Ova and water pushed 
twice with ¼ hydrodynamic volume with trapper. B) Loaded with 30μL (3/4 the hydrodynamic 
volume) of 25mg/mL Ova and water pushed once with ½ and once with ¼ hydrodynamic volumes 
with trapper. C) Loaded with 40μL (1X the hydrodynamic volume) of 25mg/mL Ova and water 
pushed once with ½ and once with ¼ hydrodynamic volume with trapper. D) Loaded with 30μL 
of 16.7mg/mL Ova and water pushed once with ½ and once with ¼ hydrodynamic volumes. E) 
Loaded with 40μL of 12.5mg/mL Ova and water pushed once with ½ and once with ¼ 
hydrodynamic volumes. F) Control GPs loaded in Tubes 
 
Form observation of the fluorescent protein loaded GPs under the microscope, the 20 μL 
initial load sample (Figure 3, panel A) had the most even distribution of fluorescent protein trapped 
inside the GPs, though the 30 μL initial load sample (panel B) also displayed a good distribution. 
Lower concentrations combined with higher volumes (panels D and E) had much poorer 
distribution, while higher volume combined with normal concentration (panel C) had a significant 
amount of trapping outside the GPs. 
The samples loaded with each concentration were tested for percent load by adding 0.1 M 
MOPS buffer and measuring florescence. The percent loaded for the varied concentration are 
shown in Table 1. 
Sample Loading Volume and 
Concentration (µL, mg/mL) 
Average % Load Standard Deviation 
1 20, 25 95.41 0.86 
2 30, 16.7 94.19 0.40 
3 40, 12.5 95.60 0.31 
 
Table 1: Average Percent Loaded for Ova in 96-Well Plate 
 
Ideal primary load conditions were established for loading particles in a 96-well plate as 
½x hydrodynamic volume with a concentration of 25mg/mL (the same as ideal conditions for 
tubes). Samples were made using these ideal conditions with three different fluorescent proteins: 
Ova, lysozyme, and IgG. These samples were added to plates of macrophages and photographed 
under a fluorescent microscope at 2 hours, 8 hours, and 24 hours in order to determine if the loaded 
particles were biologically active (Figure 4). 
 
 
Figure 4: Macrophage Plates of GPs Loaded with Fluorescent Protein in 96-Well Plates vs 
Traditional Tube Loading 
Fluorescent proteins (lysozyme, Ovalbumin, and Immunoglobulin) loaded GPs were added to 
macrophages.  A positive control was included using Green Fluorescent Protein labeled GPs 
(GFPs) and a negative control was included using blank GPs. Pictures were taken under a 
fluorescent microscope at 2 hours, 8 hours, and 24 hours. 
 
The cells of the two hour time point contain small fluorescent dots, which are the GPs with 
fluorescent protein trapped inside them. By the 8 hour mark, the florescence began to spread out 
inside the cell from fluorescent protein release. This trend continued over the 24 hour period until 
everything broke down and began dissipating. 
 
 
10.2 Optimization of GP-NH2 + SATA reaction and alternative 
conjugation approach using DAT 
10.2.1 Evaluation of polyamine-coupled, SATA reacted GPs 
In order to continue the testing of binding SATA to amine-derivatized GPs, stocks of 
amine-coupled GPs were synthesized using adaptations of protocols developed by the Ostroff lab. 
Five amines were tested: low MW chitosan (~15000 g/mol), linear PEI (25000 g/mol), branched 
PEI (600 g/mol), DAP (74.12 g/mol), and protamine (5100 g/mol) (Figure 6). 
 
Figure 5: Polyamine chemical structures 
(A) The proposed backbone structure of the human protamine-DNA complex (Biegeleisen, 2006). 
(B) Branched PEI. (C) Linear PEI. (D) Low MW Chitosan. (E) DAP. 
 
  
In the next coupling experiment, branched PEI and low MW chitosan were examined in 
place of DAP and protamine. The sodium borohydride reaction time was increased and the reaction 
was allowed to run to completion. Parafilm was used to cover the tops of the microcentrifuge tubes 
to prevent bubbling over. However, product was still lost through small “breathing holes” in the 
Parafilm. 
Enough product from each coupling reaction remained for quantification of available 
surface amine groups through fluorescent heparin binding. Since a Zetasizer could not be used to 
measure the surface charge of the amine-modified GPs, heparin was used as an indirect 
measurement of charge. Negatively charged heparin will bind strongly with the positively charged 
GP surface amine groups. Therefore, measurement of fluorescent heparin remaining in solution 
gives an indirect measurement of heparin bound to GPs after subtraction from the measured 
fluorescence of a positive control containing equal, initial unreacted heparin in solution. Each 
sample was titrated with varying amounts of heparin and fluorescence values of the supernatants 
were measured (Appendix, Data Table 1). EC50 values were calculated based off the equation 
generated from the % binding values (Appendix, Data Table 2) plotted in Figure 6. 
 Figure 6: Heparin binding assay of GPs bound with protamine, DAP, branched PEI, linear 
PEI, and Low MW Chitosan 
Polyamine-conjugated GPs were reacted with heparin in solution and fluorescence was measured 
at an excitation wavelength of 494 nm and an emission wavelength of 519 nm. The amount of 
fluorescence in solution indirectly correlates with GP surface primary amine residues bound by 
heparin. 
 
 
The values showed that GPs modified with linear PEI, low MW chitosan, and branched 
PEI bound the most heparin and would be predicted to be most reactive with SATA, so these three 
amine polymers were used to synthesize more stock GPs for further testing. For creating new 
stocks, 15 mL conical tubes were used in place of 1 mL microcentrifuge tubes. In order to quench 
the reaction completely, 0.50 mL of glycine was used instead of 0.25 mL. No product was lost due 
to bubbling. 
  
Heparin binding was, again, used to assess the binding capacity of linear PEI, branched 
PEI, and low MW chitosan. However, plotted values generated unreadable results, so another assay 
was done and fluorescence values were measured (Appendix, Data Table 3). The second heparin 
binding assay with these samples gave measureable results (Figure 7). Linear PEI showed the 
greatest binding of 65% at 1 µg of heparin added (Appendix, Data Table 4). 
 
Figure 7: Heparin binding assay of GPs bound with branched PEI, linear PEI, and Low MW 
Chitosan 
Polyamine-conjugated GPs were reacted with heparin in solution and fluorescence was measured 
at an excitation wavelength of 494 nm and an emission wavelength of 519 nm. The amount of 
fluorescence in solution indirectly correlates with GP surface primary amine residues bound by 
heparin. 
 
SATA reaction conditions, including pH and [SATA], were tested and the most reactive 
GP-amine synthesized compound was chosen through Ellman’s Assay (Appendix, Data Tables 5-
8). For examining buffer pH, a graph of % binding of each sample versus buffer pH was plotted 
(Figure 8). Linear PEI showed the only change in moles of sulfhydryl bound with varying buffers. 
The other samples showed a relatively constant, low output of moles of sulfhydryl bound with 
varying buffers (less than 1E-08 moles of thiol per 0.2 mg GPs). Sodium carbonate buffer (0.1 M, 
pH = 9.2) gave the highest binding with linear PEI (1.47E-08 moles of thiol per 0.2 mg GPs). 
 
Figure 8: SATA binding assay examining pH=7 and pH=8 phosphate buffer and pH=9.2 
sodium carbonate buffer 
Polyamine-conjugated GPs were reacted with heparin in solution and fluorescence was measured 
at an excitation wavelength of 494 nm and an emission wavelength of 519 nm. The amount of 
fluorescence in solution indirectly correlates with GP surface primary amine residues bound by 
heparin. 
 
For the following SATA experiment, different concentrations of SATA were examined in 
pH = 9.2 sodium carbonate buffer. A graph of theoretical moles of sulfhydryl put in versus moles 
of sulfhydryl out was plotted (Figure 9).SATA reaction increased as the amount of SATA added 
to each amine-coupled GP sample increased. However, no plateau was shown, indicating that a 
higher concentration of SATA may be needed in order to completely saturate the coupling reaction. 
 Figure 9: SATA binding assay examining SATA concentration 
Polyamine-conjugated GPs were reacted with heparin in solution and fluorescence was measured 
at an excitation wavelength of 494 nm and an emission wavelength of 519 nm. The amount of 
fluorescence in solution indirectly correlates with GP surface primary amine residues bound by 
heparin. 
 
Only linear PEI was used in the following experiment. Since the previous highest 
concentration of SATA showed no plateau in binding capacity, higher concentrations of SATA 
were tested (Appendix, Data Tables 9-10). The two highest concentrations of SATA (0.1 M and 
0.33 M) displayed a plateau of binding (Figure 10), suggesting that 0.1 M is the highest 
concentration needed to fully saturate the reductive amination reaction. 
 Figure 10: SATA binding assay examining SATA concentration using GPs bound with linear 
PEI 
Linear PEI-conjugated GPs were reacted with heparin in solution and fluorescence was measured 
at an excitation wavelength of 494 nm and an emission wavelength of 519 nm. The amount of 
fluorescence in solution indirectly correlates with GP surface primary amine residues bound by 
heparin. 
 
Since the control GPs showed similar binding to the linear PEI-coupled GPs, another 
experiment was done to determine if the linear PEI indeed bound to the GPs (Appendix, Data 
Tables 11-12). Results showed that the linear PEI-coupled GPs bound SATA no more efficiently 
that control GPs coupled with no amine polymer, suggesting three possibilities (Figure 11): the 
linear PEI did not bind in the initial reaction, the GPs have uncoupled over time, or the rhodamine-
heparin had degraded. 
 Figure 11: SATA binding assay examining Linear PEI versus blank GPs 
Linear PEI-conjugated GPs were reacted with heparin in solution and fluorescence was measured 
at an excitation wavelength of 494 nm and an emission wavelength of 519 nm. The amount of 
fluorescence in solution indirectly correlates with GP surface primary amine residues bound by 
heparin. 
 
The fluorescent labeler, rhodamine-heparan, was tested through a direct reaction with a 
solution of linear PEI. Solid formation would suggest a working labeler, while no formation of a 
solid would suggest a degraded fluorescent labeler. The rhodamine-heparin/linear PEI test showed 
no solid formation, showing that the fluorescent labeler was degraded. A new stock of rhodamine-
heparin was made and the heparin binding experiments were repeated (Appendix, Data Tables 13-
14). However, similar binding data was gathered and inconsistent results persisted (Figure 12). 
Therefore, the original amine-coupled GPs were remade using a reductive amination protocol 
constructed by Jessica Cohen. 
 Figure 12: Heparin binding assay reexamining GPs bound with branched PEI, linear PEI, 
and Low MW Chitosan 
Polyamine-conjugated GPs were reacted with heparin in solution and fluorescence was measured 
at an excitation wavelength of 494 nm and an emission wavelength of 519 nm. The amount of 
fluorescence in solution indirectly correlates with GP surface primary amine residues bound by 
heparin. 
 
With slight modifications, the new procedure, outlined in the Methods section, was carried 
out and new stocks of polyamine-coupled GPs were made. Heparin binding was used to assess the 
binding capacity of the amine-coupled GPs and calculate EC50 values of each synthesized sample. 
EC50 values were calculated from the equation generated by the titration curve of % binding 
values versus log[heparin] (Figure 13). The values showed that Linear PEI GPs (3 112013) and 
Branched PEI GPs (4 112013) bound heparin efficiently with EC50 values of 3.16 * 10-8 mol 
heparin/mg GPs and 2.94 * 10-8 mol heparin/mg GPs, respectively. Low MW Chitosan GPs (2 
112013) bound with an EC50 value of only 5.35 * 10-9 mol heparin/mg GPs. 
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Figure 13: GP-amine titration with heparin 
Polyamine-conjugated GPs were reacted with heparin in solution and fluorescence was measured 
at an excitation wavelength of 494 nm and an emission wavelength of 519 nm. The amount of 
fluorescence in solution indirectly correlates with GP surface primary amine residues bound by 
heparin. 
 
The heterobifunctional crosslinker SATA was bound to each newly synthesized polyamine 
GP sample. Concentration of SATA reacted with each sample was calculated based on previously 
measured EC50 values from the heparin binding assay. Synthesized amine/SATA GP samples 
were suspended in saline at 10 mg/mL or 5E09 GP/mL particle concentration and stored at -20ºC 
for later, final quantification of sulfhydryl groups through Ellman’s Assay. 
 
10.3 Alternative conjugation approach using DAT 
10.3.1 Evaluation of DAT-coupled GPs 
A series of experiments were performed to assess the ability of 2,2'-dithiolethyl bis(4-
azido-2,3,5,6-tetrafluorobenzoate to introduce sulfhydryls onto GPs by varying compound 
concentration and photo-activating light sources. In the first coupling experiment to quantify the 
binding capacity of GPs with 2,2'-dithiolethyl bis(4-azido-2,3,5,6-tetrafluorobenzoate), a dilution 
series of the compound was prepared in 20% DMSO and reacted with GPs under a 15 Watt, 254 
nm UV lamp (Appendix, Data Tables 15-19). The distance between the samples and the UV light 
source was minimized to avoid light intensity dissipation. The modified GPs were reacted with 
Ellman’s Reagent, and the recorded absorbance values reflected a minimal increase in moles of 
sulfhydryl bound as compound added increased (Figure 14). A duplication of this procedure 
showed similar low, inconsistent results (Figure 15). 
 
Figure 14: Titration to determine the lowest amount of compound needed to fully couple 
with a constant amount of GPs (n = 1). 
DAT-conjugated GPs subjected to a 15 W, 254 nm UV lamp in 20% DMSO were reacted with 
Ellman’s Reagent and absorbance of TNB2- in solution was measured at a wavelength of 412 nm. 
The amount of TNB2- in solution directly correlates with GP surface thiol residues displaced by 
Ellman’s Reagent in solution. 
 
 Figure 15: Titration to determine the lowest amount of compound needed to fully couple 
with a constant amount of GPs (n = 2). 
DAT-conjugated GPs subjected to a 15 W, 254 nm UV lamp in 20% DMSO were reacted with 
Ellman’s Reagent and absorbance of TNB2- in solution was measured at a wavelength of 412 nm. 
The amount of TNB2- in solution directly correlates with GP surface thiol residues displaced by 
Ellman’s Reagent in solution. 
 
Notably, an orange/brown solid was appearing in solution during the photo-activation 
reaction, so a reaction of only compound in 20% DMSO was carried out (Appendix, Data Table 
20). The solid appeared, and the resulting solution was centrifuged and dissolved in DMSO. The 
solid went back into solution, suggesting it was simply unreacted compound. A white solid 
material was also seen coming out of solution after addition of the compound to GPs to make a 
final solution of 20% DMSO. This problem was solved by increasing DMSO concentration until 
the compound dissolved into solution. A solution of 85% DMSO was necessary to keep 1 mg of 
DAT dissolved in a 500 L reaction volume. 
A reaction using 85% DMSO was carried out under 15 W, 254 nm UV light (Appendix, 
Data Tables 21-23). Based on Ellman’s assay absorbance, no coupling of DAT to GPs was shown 
(Figure 16). On average, less than 1E-06 micromoles of thiol bound per 0.2 mg of GPs for any 
sample. Therefore, a new light source (copying machine) was used to initiate the reaction 
(Appendix, Data Tables 24-26). Each sample was flashed 33 times using a copy machine in an 
attempt to stimulate the reaction to proceed. Ellman’s Assay absorbance values gathered from each 
sample showed no coupling of compound (Figure 17). Only one sample bound higher than 1E-06 
micromoles of thiol per 0.2 mg of GPs, but even that value (3.84E-06 micromoles thiol per 0.2 mg 
GPs) was significantly lower than the theoretical maximum possible moles of thiol bound per mg 
of GPs using this method (5.55 E-06 moles per 1 mg GPs) 
 
Figure 16: A titration to determine the lowest amount of compound needed to fully couple 
with a constant amount of GPs (n = 2) in 85% DMSO 
DAT-conjugated GPs subjected to a 15 W, 254 nm UV lamp in 85% DMSO were reacted with 
Ellman’s Reagent and absorbance of TNB2- in solution was measured at a wavelength of 412 nm. 
The amount of TNB2- in solution directly correlates with GP surface thiol residues displaced by 
cysteine in solution. 
 
 Figure 17: A titration to determine the lowest amount of compound needed to fully couple 
with a set amount of GPs (n = 2) using a copy machine 
DAT-conjugated GPs subjected to a copying machine flash in 85% DMSO were reacted with 
Ellman’s Reagent and absorbance of TNB2- in solution was measured at a wavelength of 412 nm. 
The amount of TNB2- in solution directly correlates with GP surface thiol residues displaced by 
Ellman’s Reagent in solution. 
 
In an effort to more rapidly initiate the coupling reaction, a 450 W, 280+ nm UV lamp was 
used as the light source (Appendix, Data Tables 27-28). The reaction was carried out under these 
new conditions, but Ellman’s Assay results proved inconclusive by producing similar results below 
1E-06 moles of thiol bound per 0.2 mg of GPs (Figure 18). Therefore, a new solvent was chosen. 
DAT was dissolved in minimal acetone (75%) and a reaction using the 450 W, 280+ nm UV lamp 
and a 75% acetone solution was done. Ellman’s assay results indicated some binding of sulfhydryl 
groups (5.81E-06 micromoles of thiol per GP) for the ratio of reacting 1 mg of DAT per 1 mg of 
particles. 
 Figure 18: A titration to determine the lowest amount of compound needed to fully couple 
with a constant amount of GPs while comparing the effects of varying reducing agents on 
theoretically coupled particles (n = 1) 
DAT-conjugated GPs subjected to a 450 W, 280+ nm UV lamp in 75% acetone and were reacted 
with Ellman’s Reagent and absorbance of TNB2- in solution was measured at a wavelength of 412 
nm. The amount of TNB2- in solution directly correlates with GP surface thiol residues displaced 
by Ellman’s Reagent in solution. 
 
GPs reacted with DAT were washed with DI water and suspended in saline at 5 mg/mL or 
1E09 GP/mL particle concentration, then stored at -20ºC for later, final quantification of sulfhydryl 
groups through Ellman’s Assay. 
 
10.3.2 Ellmans Assay – thiol standard curve 
In order to quantify sulfhydryl groups bound to GPs, Ellman’s assay with a standard curve 
using cysteine was created and used (Figure 19). 
 Figure 19: Thiol standard curve for quantification of free sulfhydryl groups 
A set standard of cysteine solutions were made and reacted with Ellman’s Reagent. Absorbance 
of TNB2- in solution was measured at a wavelength of 412 nm. The amount of TNB2- in solution 
directly correlates with thiol residues displaced by Ellman’s Reagent in solution. 
 
The recorded absorbance directly corresponded with moles of sulfhydryl bound by 
Ellman’s Reagent within the linear range (A ~0.01 - 2). The standard curve gave the equation and 
R2 value: 
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 = 8.1329 ∗ µ𝑀 𝐶𝑦𝑠𝑡𝑒𝑖𝑛𝑒 
𝑅2 = 0.9999 
The cysteine standard established through Ellman’s assay was used to convert all Ellman’s 
assay results of modified particles into free moles of thiol per GP. 
 
y = 8.1329x
R² = 0.9999
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
0 0.05 0.1 0.15 0.2
A
b
so
rb
an
ce
uM Cysteine
Abs Vs Conc.
Linear (Abs Vs Conc.)
10.3.3 Ellman’s Assay of SATA-conjugated and DAT-conjugated GP samples 
With polyamine/SATA-conjugated and DAT-conjugated particles successfully made, 
Ellman’s assay was used to quantify the number of available thiol groups for each sample (Table 
2). Measurement of TNB2- in solution from Ellman’s assay revealed that DAT-coupled GPs bound 
more Ellman’s Reagent (molecules of Ellman’s Reagent = molecules of thiol) per GP than Low 
MW Chitosan-coupled GPs. However, both Linear PEI-coupled GPs and Branched PEI-coupled 
GPs bound more Ellman’s Reagent per mg of GPs than DAT-coupled GPs. 
Derivatization Molecules of thiol per GP 
DAT 6926 
Low MW Chitosan-SATA 2931 
Linear PEI-SATA 59260 
Branched PEI-SATA 70230 
 
Table 2: Summary of SATA-GP and DAT-GP Ellman’s Assay 
 
10.3.4 N-Pyr(Cys) Assay – Cys-containing peptide standard curve 
In order to quantify the amount of N-Pyr(Cys) peptide bound to GPs, a standard curve 
binding cysteine with free peptide was created (Figure 20). Free peptide in solution was bound to 
varying concentrations of free cysteine to create a linear plot of absorbance versus concentration 
of pyridine. 
 Figure 20: N-Pyr(Cys) peptide standard for quantification of active thiol groups 
A set standard of cysteine solutions were made and reacted with free N-Pyr(Cys) Ova peptide. 
Absorbance of pyridine in solution was measured at a wavelength of 405 nm. The amount of 
pyridine in solution directly correlates with thiol residues displaced by cysteine in solution. 
 
Measurement of pyridine concentration directly represented the amount of peptide bound 
by cysteine within the linear range (A ~0.01 - 2). The standard curve gave the equation and R2 
value: 
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 = 0.7487 ∗ mM Pyridine 
𝑅2 = 0.9892 
The pyridine standard was used to convert all N-Pyr(Cys) Ova peptide binding assay 
absorbance results into moles of peptide bound per GP. 
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10.3.5 N-Pyr(Cys) Ova peptide binding assay of SATA-conjugated and DAT-
conjugated GP samples 
N-Pyr(Cys) peptides selectively react with free thiol groups, forming disulfide bonds. This 
covalent linkage creates a protected sulfhydryl group that prevents peptide S-S dimers from 
forming. The N-terminal pyridine broken off into solution provides a colored reaction product to 
measure direct peptide conjugation efficiency at 405 nm. Analysis of N-Pyr(Cys) Ova peptide 
binding to SATA-conjugated and DAT-conjugated GP samples revealed that SATA-derivatized 
GPs bound Cys-containing peptides more efficiently than DAT-derivatized GPs (Table 3). 
GP Type mol Pyr/mg GP 
DAT GPs 1.215 * 10-8 
Linear PEI-SATA GPs 1.897 * 10-8 
 
Table 3: N-Pyr(Cys) Ova peptide binding results 
 
However, in comparison with the Ellman’s assay results quantifying free thiol groups, 
DAT used 6 times more available thiols to bind the N-Pyr(Cys) Ova peptide, suggesting that DAT-
modified GPs bind and then release Cys peptide more efficiently than SATA-modified GPs. 
 
10.4 Demonstration of biological utility of GP peptide 
10.4.1 OT-II cell proliferation assay 
 In order to demonstrate whether N-Pyr(Cys) Ova peptide-encapsulated GPs and 
Ovalbumin-loaded GPs can effectively deliver antigen  to T-cells, an in vitro [3H]-thymidine T-
cell proliferation assay was performed (Figure 7). CD4+ T-cells obtained from OT-II mice were 
stimulated in vitro with GPs bound with N-Pyr(Cys) Ova peptide and GPs loaded with Ovalbumin. 
The results indicated that DAT surface-derivatized GP-N-Pyr(Cys) led to an enhanced CD4+ T-
cell proliferation, compared to polymer/SATA-derivatized GPs (30000 CPM compared to 8000 
CPM). This assay demonstrated that the N-Pyr(Cys) peptide was delivered, processed, and 
presented by dendritic cells more efficiently with DAT-bound GPs than with polymer/SATA-
bound GPs. 
For GP loaded Ovalbumin samples, the plate-loaded samples showed the same biological 
activity as the tube-loaded samples (50000-70000 CPM), suggesting that high-throughput GP 
loading in 96-well plates using Ovalbumin is as efficient a method as the standard GP loading 
procedure. In addition, GPs loaded with lysozyme/BSA stimulated a minimal cell response in both 
the 96-well plate and the tube (~8000 CPM). However, GPs loaded with IgG/BSA did stimulate 
T-cell proliferation (60000-70000 CPM), suggesting that there is some other factor allowing IgG 
to stimulate OT-II T-cell response. 
Tube Name 
1 Saline 
2 conA 
3 Blank GPs 
4 Ova 1, Plate/Tube 
5 Ova 1, Tube 
6 Ova 2, Tube 
7 Ova 3, Tube 
8 Ova 1, Plate 
9 Ova 2, Plate 
10 Ova 3, Plate 
11 Lys, Tube 
12 Lys, Plate 
13 IgG, Tube 
14 IgG, Plate 
15 Ova 2, DAT/SATA 
16 DAT, Ova 
17 DAT, control 
18 SATA, Ova 
19 SATA, control 
 
Table 4: OT-II T-cell Legend 
 
 Figure 21: OT-II T-cell proliferation assay of loaded and bound GPs 
A [3H]-thymidine T-cell incorporation assay was performed by stimulating OT-II T-cells using 
compounds listed in Table 4. Results for were measured using Wallac 1450 Microbeta® beta 
counter in counts per minute (CPM) and the CPM values were plotted. 
  
11 Discussion 
11.1 High-throughput GP protein loading in 96-well plates 
The current method for loading GPs involves tedious hand mixing and waiting in between 
steps. If loading could be done without mixing, then this process could be done in a 96-well plate. 
In order to determine if mixing by hand is necessary, GPs were loaded with dye inside of a 96-
well plate. This experiment involved testing several loading volumes and each variable 
combination was tested with hand mixing and without.  Figure 2 shows that the Trypan Blue dye 
distributed relatively evenly without hand mixing. Some wells had more dye then necessary, so 
those loading volumes were ruled out for later experimentation. The volume that appeared to 
distribute well enough for further testing were ½x the hydrodynamic volume of the particles, which 
is the amount used for standard protein loading into particles using the original tube loading 
method. Using ¾x and 1x the hydrodynamic volume also appeared to distribute evenly, so these 
volumes were examined further. 
 The dye experiments allowed for a rough visual estimate of which loading volumes were 
most effective in the plate, but the dye was not able to give quantitative results. Therefore, further 
experiments using fluorescent proteins were necessary. GPs were loaded with the original ½x 
hydrodynamic volume as well as with ¾x and 1x the hydrodynamic volume. These two loading 
volumes were done both by varying the overall volume added as well as by varying the 
concentration but not the volume. Figure 3 shows images of these fluorescent particles under the 
microscope. From the figure, the particles clearly contained fluorescence, which visibly 
demonstrates that the loading worked. Comparing the different loading variations under the 
microscope led to the conclusion that the original ½x loading volume achieves the best distribution 
in the plate. This conclusion is based on the even distribution of fluorescence among GPs in the 
samples examined under the fluorescent microscope. 
To further support this conclusion, fluorescence readings were taken after adding 0.1 M 
MOPS buffer to the samples to make the resulting pH = 7.4. This pH balance allowed for a 
quantitative analysis of the amount of fluorescence present in the particles. Table 1 clearly shows 
the difference in loading amount between the different loading volumes. This table also shows that 
both the original ½x and the 1x hydrodynamic volumes produce over 95% loading in the plate 
loading format. Though the 1x hydrodynamic volume produced a slightly higher percent loading, 
there was more fluorescence shown to be trapped outside of the particles when examined under 
the microscope. Therefore, using ½x the hydrodynamic volume for the initial protein load is still 
a better option for loading particles in the plate. The percent loaded into the GPs in the plate is 
definitely high enough to utilize a 96-well plate format a viable high-throughput option. 
After establishing that using a 96-well plate is a feasible GP loading method, the loading 
of different-sized protein molecules was examined. The three proteins which we tested loading for 
were: Ovalbumin (45 kDa), Lysozyme (15 kDa), and IgG (150 kDa). The results showed that only 
Ovalbumin loaded with high efficiency (98.78%), while the percent loading for Lysozyme was 
67.99% and the percent loading for IgG was 56.46%. Lysozyme and IgG may not have loaded 
efficiently due to size restrictions. Lysozyme is a small protein in comparison to Ova, so diffusion 
into and out of the particles may have occurred more freely, balancing the equilibrium. With a 
balanced equilibrium, the concentration of lysozyme outside of the particles would be equal to the 
concentration inside of the particles, so when subjected to yeast tRNA trapping, efficiency would 
be shown to be around 50%. As for IgG, the larger size may have made diffusion into the particles 
more difficult. If mixed more vigorously or for a longer period of time, more IgG molecules may 
have entered the GPs, giving a higher loading efficiency. Besides size restrictions, the lysozyme 
may have loaded less efficiently in comparison to Ova due to the use of (Bovine Serum Albumin) 
BSA as a conjugate matrix in the lysozyme and IgG samples. Ovalbumin forms a matrix with yeast 
tRNA, trapping both inside the GPs. However, lysozyme and IgG do not form a matrix with yeast 
tRNA, so BSA was mixed in and used as a substitute for matrix formation. The addition of BSA 
to lysozyme and IgG may have given an unfavorable interaction that decreased the percent loading 
of both compounds into the particles. Overall, IgG and lysozyme were not shown to load efficiently 
into GPs, whereas Ovalbumin did load efficiently. 
The final step to determining if GPs can be loaded efficiently in a 96-well plate was to 
show that the loaded particles were biologically active. This goal was accomplished by adding 
three GP samples loaded with fluorescent proteins (FL-Ova, FL-lysozyme, and FL-IgG) to 
macrophage cells and examining uptake. Figure 3 shows that, after 2 hour incubation, the 
macrophages ingested the GPs, shown as a small fluorescent punctate. After 8 hours, the particles 
began to break down and the fluorescent contents spread throughout the cell. By 24 hours the 
fluorescence began to dissipate. The appearance of fluorescence between samples varied due to 
the use of different fluorescent labels. Ovalbumin was labeled using fluorescein isothiocyanate 
(FITC), while IgG and lysozyme were labeled using Alexa-Fluor 488 dye, which produced a 
significantly stronger response to excitation and emission at wavelengths 495 nm and 519 nm, 
respectively. Therefore, IgG-loaded and lysozyme-loaded GPs appeared brighter than Ova-loaded 
GPs under a fluorescent microscope at 20x. The eventual diffusion and fading of the fluorescence 
in the cells showed that the particles were biologically active and that loading in a 96-well plate 
produced bioactive GPs. 
 
11.2 Optimization of GP-NH2 + SATA reaction and alternative 
conjugation approach using DAT 
Methods for binding cysteine-containing peptides to GPs have been previously developed 
by the Ostroff lab using the heterobifunctional crosslinker SATA. The process of reductive 
amination links amine-containing polymers to the surface aldehydes of periodate oxidized GPs. 
The subsequent reaction of SATA with amine-coupled GPs yields terminal sulfhydryl groups used 
for cysteine-containing peptide linkage through disulfide bonds. Previous attempts at this peptide 
coupling method worked but amines unreacted with SATA led to ionic interactions between acidic 
cysteine-containing peptides and the polyamines on the surface of the particles (Negmetzhanov, 
2012). A salt wash work around was developed to release any peptide bound by ionic interactions, 
but this method decreases the efficiency of the overall reaction. Methods to avoid these ionic 
interactions were sought but none proved successful. Ionic interactions seemed to have remained 
even in final N-Pyr(Cys) binding reactions, which produced un-cleavable peptide. Although the 
SATA GPs bound more peptide than DAT GPs, T-cell response was minimal, which was 
indicative of biologically inactive ionically bound peptide. Altering pH, buffers, and 
concentrations of reactants had minimal effect on altering overall SATA reaction efficiency. 
However, the polyamines linear PEI and branched PEI both gave higher binding efficiency than 
low MW chitosan, which was the polymer of choice in previously defined procedures. The heparin 
binding assay showed that linear PEI GPs and branched PEI GPs bound heparin efficiently with 
EC50 values of 3.16 * 10-8 mol heparin/mg GPs and 2.94 * 10-8 mol heparin/mg GPs, respectively, 
while low MW Chitosan GPs only bound with an EC50 value of only 5.35 * 10-9 mol heparin/mg 
GPs. In the future, a smaller primary amine linker for GP and SATA could be examined. Linear 
PEI, with a compact, linear structure, showed great peptide binding results and may have shown 
efficient biological activity as well if used instead of branched PEI. Branched PEI, with a bulky 
structure, bound peptide well but most likely contained interfering charged amine residues 
decreasing biological activity. A short, low MW (<600 Da), linear polyamine may produce fewer 
charged, free amine groups and would not be sterically problematic for SATA linking. 
To overcome the limitations of the SATA coupling approach a novel process for linking 
cysteine-containing peptides to the surface of GPs was pursued. Similar to reductive amination, 
nitrene chemistry was used in an attempt to directly link a sulfhydryl-containing compound to the 
surface of the GPs. By using a powerful, low wavelength UV lamp, the azide group of the 
compound DAT could be broken down into a nitrene, which reacts with C-H groups on the outside 
of the GP shell (Hermanson, 1996). This covalent bond would produce a reducible sulfhydryl bond 
in the center of the bound compound, similar to the SATA linkage. The overall reaction time is 30 
minutes, while the combined reaction times for the polyamine/SATA method is over 3 days for 
creation of free sulfhydryl groups. Therefore, this new reaction would offer the same result in 
significantly less time. However, results showed that using the DAT compound gave 10-fold less 
free, active thiol groups per particle than did the SATA compounds. Ellman’s Assay used to 
measure incorporated thiol onto the branched PEI-labeled SATA particles showed 7.10 * 104 
molecules of thiol bound per GP, while DAT particles showed 7.00 * 103 molecules of thiol bound 
per GP. 
After creating free sulfhydryl groups on the surface of GPs, biological activity of the 
particles is examined through the binding of cysteine-containing peptides. N-Pyr(Cys) Ova peptide 
ligates with sulfhydryl groups, knocking off one pyridine molecule per peptide into solution. The 
concentration of these pyridine molecules can be read by measuring absorbance at 405 nm. The 
results showed that the DAT-modified GPs bound fewer moles of peptide per GP than did the 
SATA-modified GPs. However, using the measured value of free sulfhydryl groups from Ellman’s 
assay, the DAT-modified GPs bound peptide to a higher percentage of free sulfhydryl groups than 
did the SATA-modified GPs. This disparity in peptide binding efficiency suggests there is some 
factor decreasing overall reaction efficiency for SATA-modified GPs in comparison to DAT-
modified GPs. Steric hindrance of the polyamine structure of branched PEI, which was the 
polymer tested through N-Pyr(Cys) Ova binding, may prevent peptide in solution from binding 
completely or ionic interactions between the N-Pyr(Cys) Ova peptide and polyamine/SATA-
modified GPs may prevent bound peptide from breaking off into solution. 
 
11.3 Demonstration of biological utility of GP peptide 
The unique structure of GPs allowed recognition and uptake by phagocytic dendritic cells 
or macrophages (APCs; antigen presenting cells) from OVA transgenic T-cell receptor (TCR) 
mice. The CD4+ OT-II T cells in these mice specifically recognize Ova peptide, allowing for 
extremely efficient Ova protein digestion into Ova peptide presentation by APCs. The MHC-II 
Ova antigens presented to CD4+ OT-II T cells  stimulated cellular proliferation measured using a 
[3H]-thymidine T-cell proliferation assay (Huang et al., 2010). GPs containing surface-linked Ova 
N-Pyr(Cys) peptide samples and GPs containing core loaded Ova protein samples were co-
cultured with APCs and CD4+ OT-II T cells to assess proliferation. OT-II T cell proliferation was 
assessed by [3H]-thymidine incorporation. Both N-Pyr(Cys) Ova-peptide derivatized GPs and Ova 
protein-loaded GPs stimulated CD4+ T-cell proliferation. Specifically, the high-throughput 
method of loading Ova protein in 96-well plates proved equally successful in comparison to Ova 
loaded into GPs using the standard technique. Both plate-loaded and tube-loaded Ova GPs saw 
upwards of 70000 CPM, indicating excellent OT-II T-cell responses due to effective antigen 
processing and presentation by APCs. Lysozyme-loaded GP samples did not induce an OT-II T-
cell response due to the absence of a reactive epitope. However, IgG-loaded GPs did produce a T-
cell response. The IgG compound may have formed a bioactive matrix with the BSA loading 
substitute, although unlikely. The IgG contained trace amounts of sheep serum albumin, but a 
cross-reactive response for OT-II T cells recognizing the Ova epitope was unlikely. During 
synthesis of the GP Ova, GP IgG, GP lysozyme, Ovalbumin may have cross-contaminated with 
the IgG samples, but this possibility is questionable because the lysozyme samples would have 
likely become contaminated as well. SDS PAGE analysis of the loaded GP vaccines could probe 
for extra bands of contaminant. If Ovalbumin were trapped in the IgG sample matrix, then a band 
would show at 45 kDa, the MW of Ovalbumin. Other than some unlikely method of contamination, 
no obvious explanations can be determined immediately. Other methods of loading IgG in GPs 
should be examined to discover the biological properties of loading IgG in GPs. These properties 
could elucidate any possible explanations for the stimulated OT-II T-cell immune response from 
GPs loaded with IgG. 
DAT modified GPs produced a stronger OT-II T cell response than branched PEI/SATA 
modified GPs. The assay showed that the N-Pyr(Cys) Ova peptide encapsulated on surface-
modified GPs using the novel compound DAT stimulated stronger Ova-specific T-cell 
proliferation in vitro compared to SATA-modified GPs despite SATA having shown 10-fold more 
binding through Ellman’s Assay. One factor influencing biological activity of each modified GP 
type may be structural capacity. DAT is a small compound in comparison to an amine polymer, 
and direct linkage of DAT to the surface of GPs yields limited steric hindrance. Large amine 
polymers bound to the GP surface provide steric hindrance for subsequent binding assays, and 
since derivatization using polyamines also requires SATA linkage, the efficiency of the succeeding 
peptide binding may be severely limited. In addition, if any amine groups remain unreacted, then 
the possibility of ionic interactions yielding un-cleavable peptide by glutathione greatly increases. 
The methods using the novel compound DAT for binding peptides onto the surface of GPs for the 
purpose of vaccine delivery should be pursued and optimized to greater enhance DAT conjugation 
so that antigen delivery and presentation through peptide binding is maximized. 
12 Conclusions and Recommendations 
High-throughput protein loading methods of GPs were established for 96-well plates and 
found to have equal biological activity using a macrophage uptake assay as compared to standard 
tube GP protein loading format. Functional testing of loaded GPs using murine transgenic OT-II 
T-cells confirmed the utility of the GP-loaded proteins for vaccine delivery in vitro. Next steps are 
to test vaccines in vivo and use this method to prepare a GP antigen protein library. Multi-step GP 
derivatization with cationic amine polymers followed by reaction with SATA gave higher GP Cys-
peptide binding efficiencies than the one-step direct reaction between GPs and the novel compound 
DAT. However, functional testing of loaded GPs using murine transgenic OT-II T-cells showed 
that the GP/DAT-linked peptides stimulated a stronger T-cell response than the GP/SATA-linked 
peptides in vitro. Future work should consist of evaluating reaction conditions to enhance the 
coupling of DAT to GPs; alternate solvents and buffer solutions should be considered to increase 
coupling efficiency. 
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14 Appendix 
Data Table 1: 5/29/2013, Heparin binding assay fluorescence readings 
Description GP (mg) Heparin (µg) Fluorescence 
Heparin Control 0 0 0 
Heparin Control 0 1 5428 
Heparin Control 0 3.3 16250 
Heparin Control 0 10 47128 
Blank GPs 0.02 0 16 
Blank GPs 0.02 1 7600 
Blank GPs 0.02 3.3 15659 
Blank GPs 0.02 10 45529 
1 51513 0.02 1 4363 
2 51513 0.02 1 4318 
3 51513 0.02 1 4043 
4 51513 0.02 1 2981 
1 52013 0.02 1 11733 
2 52013 0.02 1 6661 
3 52013 0.02 1 711 
4 52013 0.02 1 6706 
1 51513 0.02 3.3 44628 
2 51513 0.02 3.3 47658 
3 51513 0.02 3.3 42241 
4 51513 0.02 3.3 40045 
1 52013 0.02 3.3 43772 
2 52013 0.02 3.3 37910 
3 52013 0.02 3.3 26792 
4 52013 0.02 3.3 35200 
1 51513 0.02 10 46750 
2 51513 0.02 10 45827 
3 51513 0.02 10 45933 
4 51513 0.02 10 42494 
1 52013 0.02 10 42083 
2 52013 0.02 10 38163 
3 52013 0.02 10 33884 
4 52013 0.02 10 41043 
 
Data Table 2: 5/29/2013, Heparin binding assay EC50 values 
Description 1 µg 3 µg 10 µg EC50 (ug heparin) EC50 (mol heparin) 
2 51513 1.031 0 1.974 28.744 1.916E-09 
3 51513 7.334 5.349 1.748 0.0577 3.849E-12 
4 51513 31.675 10.269 9.104 0.301 2.005E-11 
2 52013 43.229 13.392 9.315 0.873 5.818E-11 
3 52013 93.940 38.792 19.483 2.357 1.572E-10 
4 52013 42.845 19.583 2.471 1.038 6.923E-11 
 
  
Data Table 3: 6/21/2013, Heparin binding assay fluorescence readings 
Name GP (mg) Heparin (µg) Fluorescence 
Heparin Control 0 0 0 
Heparin Control 0 1 3024 
Heparin Control 0 3.3 15513 
Heparin Control 0 10 40313 
Blank GPs 0.02 0 7 
Blank GPs 0.02 1 4397 
Blank GPs 0.02 3.3 17162 
Blank GPs 0.02 10 47482 
1 61013 0.02 1 4659 
2 61013 0.02 1 3686 
3 61013 0.02 1 3898 
4 61013 0.02 1 1630 
5 61013 0.02 3.3 16569 
6 61013 0.02 3.3 16670 
7 61013 0.02 3.3 14813 
8 61013 0.02 3.3 16362 
9 61013 0.02 10 46683 
10 61013 0.02 10 43804 
11 61013 0.02 10 40115 
12 61013 0.02 10 45096 
 
Data Table 4: 6/21/2013, Heparin binding assay EC50 values 
Description 1 3 10 EC50 (µg heparin)  EC50 (mol heparin) 
2 62113 20.88 0 6.17 -  - 
3 62113 16.33 10.60 14.07 -  - 
4 62113 65.01 1.249 3.40 1.323 8.82E-11 
 
Data Table 5: 6/28/2013, SATA binding protocol examining buffer pH description 
Old Tube New Tube Description GP-polymer (mg) pH buffer [SATA] (M) 
1 61013 1 62813 Control 0.2 7 phos. 0.01 
2 61013 2 62813 Low MW Chitosan 0.2 7 phos. 0.01 
3 61013 3 62813 Linear PEI 0.2 7 phos. 0.01 
4 61013 4 62813 Branched PEI 0.2 7 phos. 0.01 
1 61013 5 62813 Control 0.2 8 phos. 0.01 
2 61013 6 62813 Low MW Chitosan 0.2 8 phos. 0.01 
3 61013 7 62813 Linear PEI 0.2 8 phos. 0.01 
4 61013 8 62813 Branched PEI 0.2 8 phos. 0.01 
1 61013 9 62813 Control 0.2 9.2 carb. 0.01 
2 61013 10 62813 Low MW Chitosan 0.2 9.2 carb. 0.01 
3 61013 11 62813 Linear PEI 0.2 9.2 carb. 0.01 
4 61013 12 62813 Branched PEI 0.2 9.2 carb. 0.01 
  - Blank 0 - 0 
  - Blank w/Ellman's 0 - 0 
 
  
Data Table 6: 6/28/2013, SATA binding protocol examining buffer pH absorbance readings 
Description Absorbance Moles out Moles in 
Control 0.0514 6.43E-09 1.00E-06 
Low MW Chitosan 0.06 7.50E-09 1.00E-06 
Linear PEI 0.0713 8.91E-09 1.00E-06 
Branched PEI 0.0726 9.08E-09 1.00E-06 
Control 0.0685 8.56E-09 1.00E-06 
Low MW Chitosan 0.0616 7.70E-09 1.00E-06 
Linear PEI 0.0901 1.13E-08 1.00E-06 
Branched PEI 0.0523 6.54E-09 1.00E-06 
Control 0.0685 8.56E-09 1.00E-06 
Low MW Chitosan 0.0657 8.21E-09 1.00E-06 
Linear PEI 0.1176 1.47E-08 1.00E-06 
Branched PEI 0.0625 7.81E-09 1.00E-06 
Blank 0 0 0 
Blank w/Ellman's 0.0403 5.04E-09 0 
 
Data Table 7: 7/01/2013, SATA binding protocol examining SATA concentration description 
Old Tube New Tube Description GP-polymer (mg) pH buffer [SATA] (M) 
1 61013 1 70113 Control 0.2 9.2 carb. 0.1 
2 61013 2 70113 Low MW Chitosan 0.2 9.2 carb. 0.1 
3 61013 3 70113 Linear PEI 0.2 9.2 carb. 0.1 
4 61013 4 70113 Branched PEI 0.2 9.2 carb. 0.1 
1 61013 5 70113 Control 0.2 9.2 carb. 0.01 
2 61013 6 70113 Low MW Chitosan 0.2 9.2 carb. 0.01 
3 61013 7 70113 Linear PEI 0.2 9.2 carb. 0.01 
4 61013 8 70113 Branched PEI 0.2 9.2 carb. 0.01 
1 61013 9 70113 Control 0.2 9.2 carb. 0.001 
2 61013 10 70113 Low MW Chitosan 0.2 9.2 carb. 0.001 
3 61013 11 70113 Linear PEI 0.2 9.2 carb. 0.001 
4 61013 12 70113 Branched PEI 0.2 9.2 carb. 0.001 
1 61013 13 70113 Control 0.2 9.2 carb. 0.0001 
2 61013 14 70113 Low MW Chitosan 0.2 9.2 carb. 0.0001 
3 61013 15 70113 Linear PEI 0.2 9.2 carb. 0.0001 
4 61013 16 70113 Branched PEI 0.2 9.2 carb. 0.0001 
  - Blank 0 - 0 
  - Blank w/Ellman's 0 - 0 
 
  
Data Table 8: 7/01/2013, SATA binding protocol examining [SATA] absorbance readings 
Description Absorbance Moles out Moles in 
Control 0.2454 3.07E-08 0.00001 
Low MW Chitosan 0.3248 4.06E-08 0.00001 
Linear PEI 0.1874 2.34E-08 0.00001 
Branched PEI 0.2342 2.93E-08 0.00001 
Control 0.0688 8.60E-09 0.000001 
Low MW Chitosan 0.0819 1.02E-08 0.000001 
Linear PEI 0.0735 9.19E-09 0.000001 
Branched PEI 0.1027 1.28E-08 0.000001 
Control 0.031 3.88E-09 0.0000001 
Low MW Chitosan 0.0318 4.00E-09 0.0000001 
Linear PEI 0.0303 3.79E-09 0.0000001 
Branched PEI 0.0345 4.31E-09 0.0000001 
Control 0.0335 4.19E-09 0.00000001 
Low MW Chitosan 0.0369 4.61E-09 0.00000001 
Linear PEI 0.0324 4.05E-09 0.00000001 
Branched PEI 0.0349 4.36E-09 0.00000001 
Blank 0 0 0 
Blank w/Ellman's 0.0338 4.23E-09 0 
 
Data Table 9: 7/08/2013, SATA binding protocol examining SATA concentration description 
Old Tube New Tube Description GP-polymer (mg) pH buffer [SATA] (M) 
1 61013 1 70813 control 0.2 9.2 carb. 0.33 
3 61013 2 70813 Linear PEI 0.2 9.2 carb. 0.33 
1 61013 3 70813 control 0.2 9.2 carb. 0.1 
3 61013 4 70813 Linear PEI 0.2 9.2 carb. 0.1 
1 61013 5 70813 control 0.2 9.2 carb. 0.01 
3 61013 6 70813 Linear PEI 0.2 9.2 carb. 0.01 
  - Blank 0 - 0 
  - Blank w/Ellman's 0 - 0 
 
Data Table 10: 7/08/2013, SATA binding protocol examining [SATA] absorbance readings 
Description Absorbance Moles out Moles in 
control 0.1373 1.716E-08 0.000033 
Linear PEI 0.1653 2.066E-08 0.000033 
control 0.2284 2.855E-08 0.00001 
Linear PEI 0.2558 3.198E-08 0.00001 
control 0.0761 9.513E-09 0.000001 
Linear PEI 0.049 6.125E-09 0.000001 
Blank 0 0 0 
Blank w/Ellman's 0.0288 3.6E-09 0 
 
  
Data Table 11: 7/30/2013, SATA binding protocol examining SATA concentration description 
Old Tube New Tube Description GP-polymer (mg) pH buffer [SATA] (M) 
1 61013 1 73013 Control 0.2 9.2 carb. 0.33 
3 61013 2 73013 Linear PEI 0.2 9.2 carb. 0.33 
1 61013 3 73013 Control 0.2 9.2 carb. 0.1 
3 61013 4 73013 Linear PEI 0.2 9.2 carb. 0.1 
1 61013 5 73013 Control 0.2 9.2 carb. 0.01 
3 61013 6 73013 Linear PEI 0.2 9.2 carb. 0.01 
  - Blank 0 - 0 
  - Blank w/Ellman's 0 - 0 
 
Data Table 12: 7/30/2013, SATA binding protocol examining [SATA] absorbance readings 
Description Absorbance moles Out Moles in 
Control 0.1417 1.771E-08 0.000033 
Linear PEI 0.0949 1.186E-08 0.000033 
Control 0.159 1.988E-08 0.00001 
Linear PEI 0.1504 1.88E-08 0.00001 
Control 0.0426 5.325E-09 0.000001 
Linear PEI 0.0472 5.9E-09 0.000001 
Blank 0.0001 1.25E-11 0 
Blank w/Ellman's 0.0282 3.525E-09 0 
 
Data Table 13: 7/26/2013, Heparin binding assay fluorescence readings 
Tube Description GP (mg) Heparin (µg) Fluorescence 
1 62113 Heparin Control 0 0 0 
2 62113 Heparin Control 0 1 2782 
3 62113 Heparin Control 0 3.3 12806 
4 62113 Heparin Control 0 10 47539 
5 62113 Blank GPs 0.02 0 -14 
6 62113 Blank GPs 0.02 1 4435 
7 62113 Blank GPs 0.02 3.3 15710 
8 62113 Blank GPs 0.02 10 49324 
9 62113 1 61013 0.02 1 4327 
10 62113 2 61013 0.02 1 2781 
11 62113 3 61013 0.02 1 1085 
12 62113 4 61013 0.02 1 3709 
13 62113 1 61013 0.02 3.3 15237 
14 62113 2 61013 0.02 3.3 15230 
15 62113 3 61013 0.02 3.3 12140 
16 62113 4 61013 0.02 3.3 13810 
17 62113 1 61013 0.02 10 47575 
18 62113 2 61013 0.02 10 44323 
19 62113 3 61013 0.02 10 45215 
20 62113 4 61013 0.02 10 47726 
 
  
Data Table 14: 7/26/2013Heparin binding assay EC50 values 
 Tube 1 µg 3 µg 10 µg 
EC50 (µg 
heparin) 
 EC50 (mol 
heparin) 
µg SATA per 
0.2 mg GP 
Mol SATA 
per 0.2 mg 
GP 
2 62113 35.729 0.0459 6.836 9.738 6.49E-10 97.38 4.21E-07 
3 62113 74.925 20.326 4.961 2.173 1.45E-10 36.21 1.57E-07 
4 62113 14.282 9.365 0 0.0340 2.26E-12 0.0136 5.88E-11 
 
Data Table 15: 6/05/2013, GP titration with DAT description 
Old Tube New Tube Description GP (mg) DAT (µg) 
  1 60613 Just buffer 0 0 
  2 60613 Just Ellman's and buffer 0 0 
2 60513 3 60613 No DAT 0.2 0 
2 60513 4 60613 No DAT - reduced 0.2 0 
3 60513 5 60613 sample 0.2 2000 
4 60513 6 60613 sample 0.2 200 
5 60513 7 60613 sample 0.2 20 
6 60513 8 60613 sample 0.2 2 
7 60513 9 60613 sample 0.2 0.2 
8 60513 10 60613 sample 0.2 0.02 
9 60513 11 60613 sample 0.2 0.002 
 
Data Table 16: 6/05/2013, GP Titration with DAT absorbance readings 
Description Absorbance Calc. mol per well Total µmol out µmol put in 
Just buffer 0       
Just Ellman's and buffer 0.0444 1.41E-13     
No DAT 0.047 1.67E-13     
No DAT - reduced 0.0875 5.72E-13     
sample 0.1528 1.225E-12 0.00000245 8.918219923 
sample 0.3855 3.552E-12 0.000007104 0.891821992 
sample 0.1021 7.18E-13 0.000001436 0.089182199 
sample 0.0619 3.16E-13 0.000000632 0.00891822 
sample 0.0547 2.44E-13 0.000000488 0.000891822 
sample 0.0495 1.92E-13 0.000000384 8.91822E-05 
sample 0.1346 1.043E-12 0.000002086 8.91822E-06 
 
  
Data Table 17: 6/10/2013, GP titration with DAT description 
Old Tube New Tube Description GP (mg) DAT (µg) 
  1 61013 Just buffer 0 0 
  2 61013 Just Ellman's and buffer 0 0 
  3 61013 No DAT 0.2 0 
  4 61013 No DAT - reduced 0.2 0 
3 60513 5 61013 sample 0.2 2000 
4 60513 6 61013 sample 0.2 200 
5 60513 7 61013 sample 0.2 20 
6 60513 8 61013 sample 0.2 2 
7 60513 9 61013 sample 0.2 0.2 
8 60513 10 61013 sample 0.2 0.02 
9 60513 11 61013 sample 0.2 0.002 
  12 61013 No DAT 0.2 0 
  13 61013 No DAT - reduced 0.2 0 
3 60513 14 61013 sample 0.2 2000 
4 60513 15 61013 sample 0.2 200 
5 60513 16 61013 sample 0.2 20 
6 60513 17 61013 sample 0.2 2 
7 60513 18 61013 sample 0.2 0.2 
8 60513 19 61013 sample 0.2 0.02 
9 60513 20 61013 sample 0.2 0.002 
 
Data Table 18: 6/10/2013, GP titration with DAT absorbance readings 
Description Absorbance Calc. mol per well Total µmol out µmol put in 
Just buffer 0       
Just Ellman's and buffer 0.056 2.57E-13     
No DAT 0.0836 5.33E-13     
No DAT - reduced 0.8454 8.151E-12     
sample 0.1068 7.65E-13 0.00000153 8.918219923 
sample 0.3111 2.808E-12 0.000005616 0.891821992 
sample 0.1229 9.26E-13 0.000001852 0.089182199 
sample 0.792 7.617E-12 0.000015234 0.00891822 
sample 0.0729 4.26E-13 0.000000852 0.000891822 
sample 0.0666 3.63E-13 0.000000726 8.91822E-05 
sample 0.0804 5.01E-13 0.000001002 8.91822E-06 
No DAT 0.0645 3.42E-13     
No DAT - reduced 0.074 4.37E-13     
sample 0.065 3.47E-13 0.000000694 8.918219923 
sample 0.0676 3.73E-13 0.000000746 0.891821992 
sample 0.0684 3.81E-13 0.000000762 0.089182199 
sample 0.0725 4.22E-13 0.000000844 0.00891822 
sample 0.1001 6.98E-13 0.000001396 0.000891822 
sample 0.0668 3.65E-13 0.00000073 8.91822E-05 
sample 0.0645 3.42E-13 0.000000684 8.91822E-06 
 
  
Data Table 19: 6/10/2013, Average and standard deviation of 61013 
New Tube µmoles in Average µmoles out Standard Deviation 
5,14 61013 8.918219923 0.000001112 5.91141E-07 
6,15 61013 0.891821992 0.000003181 3.44361E-06 
7,16 61013 0.089182199 0.000001307 7.70746E-07 
8,17 61013 0.00891822 0.000008039 1.01753E-05 
9,18 61013 0.000891822 0.000001124 3.84666E-07 
10,19 61013 8.91822E-05 0.000000728 2.82843E-09 
11,20 61013 8.91822E-06 0.000000843 2.2486E-07 
 
Data Table 20: 6/10/2013, Self-titration with DAT description 
Old Tube New Tube Description GP (mg) DAT (µg) 
  1 61213 Just buffer 0 0 
  2 61213 Just Ellman's and buffer 0 0 
2 6113 3 61213 No DAT 0 0 
2 61113 4 61213 No DAT - reduced 0 0 
3 61113 5 61213 sample 0 2000 
4 61113 6 61213 sample 0 200 
5 61113 7 61213 sample 0 20 
6 61113 8 61213 sample 0 2 
7 61113 9 61213 sample 0 0.2 
8 61113 10 61213 sample 0 0.02 
9 61113 11 61213 sample 0 0.002 
 
Data Table 21: 6/12/2013, GP titration with DAT description 
Old Tube New Tube Description GP (mg) DAT (µg) 
  1 61313 Just buffer 0 0 
  2 61313 Just Ellman's and buffer 0 0 
2 61213 3 61313 No DAT 0.2 0 
2 61213 4 61313 No DAT - reduced 0.2 0 
3 61213 5 61313 sample 0.2 200 
4 61213 6 61313 sample 0.2 20 
5 61213 7 61313 sample 0.2 2 
6 61213 8 61313 sample 0.2 0.2 
7 61213 9 61313 sample 0.2 0.02 
8 61213 10 61313 sample 0.2 0.002 
2 61213 11 61313 No DAT 0.2 0 
2 61213 12 61313 No DAT - reduced 0.2 0 
3 61213 13 61313 sample 0.2 200 
4 61213 14 61313 sample 0.2 20 
5 61213 15 61313 sample 0.2 2 
6 61213 16 61313 sample 0.2 0.2 
7 61213 17 61313 sample 0.2 0.02 
8 61213 18 61313 sample 0.2 0.002 
 
  
Data Table 22: 6/12/2013, GP titration with DAT absorbance readings 
Description Absorbance Calc. moles per well Total µmoles out µmol put in 
Just buffer 0       
Just Ellman's and buffer 0.0542 2.39E-13     
No DAT 0.0705 4.02E-13     
No DAT - reduced 0.0682 3.79E-13     
sample 0.0697 3.94E-13 0.000000788 0.891821992 
sample 0.0657 3.54E-13 0.000000708 0.089182199 
sample 0.0663 3.6E-13 0.00000072 0.00891822 
sample 0.0874 5.71E-13 0.000001142 0.000891822 
sample 0.0723 4.2E-13 0.00000084 8.91822E-05 
sample 0.0642 3.39E-13 0.000000678 8.91822E-06 
No DAT 0.0657 3.54E-13     
No DAT - reduced 0.0777 4.74E-13     
sample 0.0789 4.86E-13 0.000000972 0.891821992 
sample 0.074 4.37E-13 0.000000874 0.089182199 
sample 0.0829 5.26E-13 0.000001052 0.00891822 
sample 0.0704 4.01E-13 0.000000802 0.000891822 
sample 0.0655 3.52E-13 0.000000704 8.91822E-05 
sample 0.0833 5.3E-13 0.00000106 8.91822E-06 
 
Data Table 23: 6/13/2013, Average and standard deviation of 61313 
New Tube µmol in Average µmol out Standard Deviation 
5,13 61313 0.891821992 0.00000088 1.30108E-07 
6,14 61313 0.089182199 0.000000791 1.1738E-07 
7,15 61313 0.00891822 0.000000886 2.34759E-07 
8,16 61313 0.000891822 0.000000972 2.40416E-07 
9,17 61313 8.91822E-05 0.000000772 9.61665E-08 
10,18 61313 8.91822E-06 0.000000869 2.70115E-07 
 
  
Data Table 24: 6/17/2013, GP titration with DAT description 
Old Tube New Tube Description GP (mg) DAT (µg) 
  1 61813 Just buffer 0 0 
  2 61813 Just Ellman's and buffer 0 0 
2 61713 3 61813 No DAT 0.2 0 
2 61713 4 61813 No DAT - reduced 0.2 0 
3 61713 5 61813 sample 0.2 200 
4 61713 6 61813 sample 0.2 20 
5 61713 7 61813 sample 0.2 2 
6 61713 8 61813 sample 0.2 0.2 
7 61713 9 61813 sample 0.2 0.02 
2 61713 10 61813 No DAT 0.2 0 
2 61713 11 61813 No DAT - reduced 0.2 0 
3 61713 12 61813 sample 0.2 200 
4 61713 13 61813 sample 0.2 20 
5 61713 14 61813 sample 0.2 2 
6 61713 15 61813 sample 0.2 0.2 
7 61713 16 61813 sample 0.2 0.02 
 
Data Table 25: 6/17/13, GP titration with DAT absorbance readings 
Description Absorbance Calc. mol per well Total µmol out µmol put in 
Just buffer 0       
Just Ellman's and buffer 0.0384 8.1E-14     
No DAT 0.0388 8.5E-14     
No DAT - reduced 0.0612 3.09E-13     
sample 0.0472 1.69E-13 0.000000338 0.891821992 
sample 0.0466 1.63E-13 0.000000326 0.089182199 
sample 0.0471 1.68E-13 0.000000336 0.00891822 
sample 0.0706 4.03E-13 0.000000806 0.000891822 
sample 0.0554 2.51E-13 0.000000502 8.91822E-05 
No DAT 0.0471 1.68E-13     
No DAT - reduced 0.1137 8.34E-13     
sample 0.0475 1.72E-13 0.000000344 0.891821992 
sample 0.0453 1.5E-13 0.0000003 0.089182199 
sample 0.2225 1.922E-12 0.000003844 0.00891822 
sample 0.0537 2.34E-13 0.000000468 0.000891822 
sample 0.0563 2.6E-13 0.00000052 8.91822E-05 
 
Data Table 26: 6/17/2013, Average and standard deviation of 61713 
New Tube µmol in Averave µmol out Standard Deviation 
5,12 61813 0.891821992 0.000000341 4.24264E-09 
6,13 61813 0.089182199 0.000000313 1.83848E-08 
7,14 61813 0.00891822 0.00000209 2.48053E-06 
8,15 61813 0.000891822 0.000000637 2.39002E-07 
9,16 61813 8.91822E-05 0.000000511 1.27279E-08 
 
  
Data Table 27: 7/10/2013, GP titration with DAT description 
Old 
Tube 
New 
Tube Description 
GP 
(mg) 
DAT 
(µg) 
Reducing agent (µL, 
type) 
  7 71013 Just buffer 0 0 0 
  8 71013 
Just Ellman's and 
buffer 0 0 0 
1 71013 9 71013 No DAT - reduced 0.2 0 10, TCEP 
2 71013 10 71013 sample 0.2 200 10, TCEP 
3 71013 11 71013 sample 0.2 20 10, TCEP 
4 71013 12 71013 sample 0.2 2 10, TCEP 
5 71013 13 71013 sample 0.2 0.2 10, TCEP 
6 71013 14 71013 sample 0.2 0.02 10, TCEP 
1 71013 15 71013 No DAT - reduced 0.2 0 10, DTT 
2 71013 16 71013 sample 0.2 200 10, DTT 
3 71013 17 71013 sample 0.2 20 10, DTT 
4 71013 18 71013 sample 0.2 2 10, DTT 
5 71013 19 71013 sample 0.2 0.2 10, DTT 
6 71013 20 71013 sample 0.2 0.02 10, DTT 
1 71013 21 71013 No DAT - reduced 0.2 0 10, B-mercaptoethanol 
2 71013 22 71013 sample 0.2 200 10, B-mercaptoethanol 
3 71013 23 71013 sample 0.2 20 10, B-mercaptoethanol 
4 71013 24 71013 sample 0.2 2 10, B-mercaptoethanol 
5 71013 25 71013 sample 0.2 0.2 10, B-mercaptoethanol 
6 71013 26 71013 sample 0.2 0.02 10, B-mercaptoethanol 
1 71013 27 71013 No DAT - reduced 0.2 0 10, PBS 
2 71013 28 71013 sample 0.2 200 10, PBS 
3 71013 29 71013 sample 0.2 20 10, PBS 
4 71013 30 71013 sample 0.2 2 10, PBS 
5 71013 31 71013 sample 0.2 0.2 10, PBS 
6 71013 32 71013 sample 0.2 0.02 10, PBS 
 
  
Data Table 28: 7/10/2013, GP titration with DAT absorbance readings 
Description Absorbance Calc. mol per well Total µmol out µmol put in 
Just buffer 0       
Just Ellman's and buffer 0.0331 2.8E-14     
No cmpnd - reduced 0.0358 5.5E-14     
sample 0.0429 1.26E-13 0.000000252 0.891821992 
sample 0.0425 1.22E-13 0.000000244 0.089182199 
sample 0.0401 9.8E-14 0.000000196 0.00891822 
sample 0.0406 1.03E-13 0.000000206 0.000891822 
sample 0.0444 1.41E-13 0.000000282 8.91822E-05 
No cmpnd - reduced 0.0373 7E-14 0.00000014 0 
sample 0.046 1.57E-13 0.000000314 0.891821992 
sample 0.0413 1.1E-13 0.00000022 0.089182199 
sample 0.0405 1.02E-13 0.000000204 0.00891822 
sample 0.0426 1.23E-13 0.000000246 0.000891822 
sample 0.0424 1.21E-13 0.000000242 8.91822E-05 
No cmpnd - reduced 0.0406 1.03E-13 0.000000206 0 
sample 0.039 8.7E-14 0.000000174 0.891821992 
sample 0.0398 9.5E-14 0.00000019 0.089182199 
sample 0.0405 1.02E-13 0.000000204 0.00891822 
sample 0.0434 1.31E-13 0.000000262 0.000891822 
sample 0.0441 1.38E-13 0.000000276 8.91822E-05 
No cmpnd - reduced 0.0382 7.9E-14 0.000000158 0 
sample 0.0388 8.5E-14 0.00000017 0.891821992 
sample 0.0387 8.4E-14 0.000000168 0.089182199 
sample 0.0397 9.4E-14 0.000000188 0.00891822 
sample 0.0381 7.8E-14 0.000000156 0.000891822 
sample 0.0416 1.13E-13 0.000000226 8.91822E-05 
 
 
 
